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Abstract: Protein formulation development relies on the selection of excipients that inhibit
protein–protein interactions preventing aggregation. Empirical strategies involve screening many
excipient and buffer combinations using force degradation studies. Such methods do not readily
provide information on intermolecular interactions responsible for the protective effects of excipients.
This study describes a molecular docking approach to screen and rank interactions allowing for the
identification of protein–excipient hotspots to aid in the selection of excipients to be experimentally
screened. Previously published work with Drosophila Su(dx) was used to develop and validate the
computational methodology, which was then used to determine the formulation hotspots for Fab
A33. Commonly used excipients were examined and compared to the regions in Fab A33 prone to
protein–protein interactions that could lead to aggregation. This approach could provide information
on a molecular level about the protective interactions of excipients in protein formulations to aid the
more rational development of future formulations.
Keywords: molecular docking; protein–excipient interactions; protein stability; molecular dynamics;
Fab formulation
1. Introduction
Therapeutic proteins are potent drug substances that are used and being widely developed to
address unmet clinical needs in oncology, inflammation, and chronic pain. Proteins are dynamic
structures susceptible to both aggregation and unfolding processes since the tertiary structure is
primarily maintained by non-covalent interactions. Excipients are used in an effort to minimise
deleterious processes leading to loss of biological activity. A key challenge is to formulate clinically
used proteins so that they can be stored without loss of biological activity.
Understanding protein–excipient interactions is important to optimise protein formulations. These
interactions can change the surface properties of the proteins and may change their secondary and
tertiary structure [1,2], which could be detrimental for protein activity. Since proteins are administered
parentally, the number of excipients that are clinically approved is limited. The formulation process
usually involves screening these excipients at different relative concentrations. These experiments are
often challenging because of the low availability of the protein of interest during preclinical studies.
Furthermore, excipient selection is often empirical or based on historical data and amino acid sequence
observation, without consideration for the protein’s three-dimensional structure. Companies seek
alternative strategies to overcome this limitation.
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The rational development of formulations derived from optimised interactions between proteins
with specific excipients that effectively contribute to their stability and efficiency would be an important
step-change in the field. Currently, there are attempts to use a combination of molecular docking and
dynamics in selection of excipients to improve drug solubility [3,4] or to define the protein surfaces
where the excipients may bind [5,6].
Molecular docking has been extensively used in drug discovery both for the design of new drugs
tailored to specific targets and to understand the interactions with known molecules that provide a
scaffold for new, improved design. Still, the potential of molecular docking techniques for formulation
design and optimisation has not been utilised to the same extent.
In this study, we focus on the use of molecular docking techniques to develop a computational
approach that will enable informed excipient selection by identifying hotspots for their interaction on
the protein surface. The novelty of this approach lies in the attempt to identify interaction surfaces
where an excipient may form favourable interactions with a protein. Excipients whose predicted
interaction surfaces coincide with protein–protein interaction surfaces potentially responsible for
protein aggregation may be good candidates for inclusion in protein formulation. The identification
of protein–excipient interaction surfaces is carried out without prior knowledge of binding sites in
contrast to well established docking methods used in structure-based drug design where the ligand
binding sites are known. Our approach fully considers the three-dimensional structure of a protein and
provides a time-efficient approach suited to be used in early formulation stages of protein therapeutics
development regardless of protein class. The development of this approach has the potential to increase
our ability to rationally design protein formulations during early preclinical development.
A well-studied protein, Drosophila Su(dx) protein (WW34), was used to develop our
computational approach to hotspot identification. Two different studies—one experimental and
one computational—inspected the role of arginine (Arg) and glutamic acid (Glu) in this protein
solubility. These studies were used as a reference for the development and validation of our approach.
Firstly, the effect of the combined addition of Arg and Glu to a solution of the WW domains
3 and 4 from Drosophila Su(dx) protein (WW34) in the reduction of intermolecular protein–protein
interactions has been studied experimentally by Golovanov et al. [7]. In this study, the authors establish
the simultaneous addition of 50 mM of Arg and Glu as a method to increase the solubility of WW34.
They studied this effect with several different proteins (WW34, Ref2NM, MAGOH, ORF57, Y14, and
TAP) over a range of conditions and found that the equimolar addition of the charged L-amino acids
Arg and Glu increased protein solubility and long-term stability without altering the ability to interact
its target proteins or RNA. Furthermore, the simultaneous addition of these two amino acids to the
buffer reduced aggregation of these proteins during concentration processes and protein degradation,
resulting in increased formulation stability [7]. These findings were reported for all the proteins in
the study, including WW34. Heteronuclear single quantum correlation (HSQC) NMR studies showed
that the addition of Arg and Glu to buffer did not cause any structural alteration of the proteins over a
period of several weeks.
The synergistic effects for the combined use of arginine and glutamic acid to increase protein
solubility was further described by Shukla et al. [8] using preferential interaction coefficients (Γ23)
and molecular dynamics. It was thought that interactions between the two amino acids (Arg and
Glu) increase their presence on the protein surface, therefore reducing the number of protein–protein
interactions. The synergistic effect of two amino acids used as excipients increased the number of Glu
and Arg molecules close to the protein surface when compared to the individual addition of Arg or
Glu only, and this synergistic effect was reported to be responsible for an increased solubility effect
on WW34 [8]. More relevant to our work, the location of excipient molecules close to the nearest
amino acid on the protein surface was determined using molecular dynamics simulation [9], and those
were reported as excipient binding sites. These sites were taken as the benchmark for our molecular
docking methodology.
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We report the development of a computational approach for excipient selection by identifying
hotspots for their interaction on the protein surface. The hotspots, preferential binding surfaces for
excipients, were identified using molecular docking. The use of this approach is further exemplified by
prediction of Fab hotspots for commercially available excipients. The excipients were used as ligands
and were selected from those used in commercial formulations of therapeutic proteins [9].
2. Results and Discussion
Protein aggregation often involves non-covalent protein–protein interactions early in the process
where nucleation, or the establishment of interacting multiple protein species, occurs. The process of
aggregation occurs more readily in unfolded forms of a protein where there are more hydrophobic
interactions possible than in the folded, active form of the protein. The tertiary structure of a folded
protein is dynamic because it is reliant on non-covalent intramolecular interactions, so specific
aggregation pathways are protein-dependent. Generally, the specific steps resulting in protein
aggregation are poorly understood [10,11], but it has been shown that low molecular weight substances
can delay or decrease aggregation [12] and protein unfolding [13]. The protective effect can be a result
of new intermolecular interactions formed between additives, such as excipients, and the protein [14].
It is well established that the formation of intermolecular interactions and their location on the protein
surface can be studied in silico using molecular docking [15].
Molecular docking is a methodology, which allows the study of the interactions between different
molecules with many software packages available for this type of study. Knowledge of the molecular
system is crucial for the decision about what type of software package to use. In general, it is possible
to classify the software packages based on the molecular system that they are generally applied
to. Often they can be either directed towards protein–protein (protein–DNA) interactions or small
molecule–protein interactions. All docking software can perform either (i) rigid docking, where the
conformation of the molecules is not altered during the docking process; or (ii) flexible docking, where
the conformation of part or whole molecules change during the best-fit search.
There are two stages in a molecular docking protocol: sampling and scoring [16]. During sampling,
a range of different conformations of a ligand (flexible docking only) and their poses, orientations of a
ligand in respect to the binding surface of the target, are generated. In the second step, these poses are
scored and ranked according to a mathematical algorithm used to predict the binding affinities. The last
step is where most software packages diverge and where the most research has been invested [17–19].
Docking software packages are usually evaluated based on the accuracy with which they predict poses
and the calculation of free energy between target and ligand.
Scoring functions of both protein–ligand and protein–protein docking software can be classified
according to how the energy terms are derived [20]. These can be force-field-based, empirical, or
knowledge-based. Force-field-based scoring functions determine physical atomic interactions in the
system, such as Van der Waals, bond terms (length, angles and torsions), and electrostatics derived from
force-field parameters. Force fields allow the determination of the energy of a system by calculating
all the forces influencing the system using classical physics and sometimes higher-level quantum
mechanics, and experimental data [18,21]. Empirical scoring functions make use of weighted energy
terms to determine binding affinities [18,22]. These functions deconvolute the free energy between
receptor and ligand (∆G) into a sum of the weighted (ωi) free binding energies for each component
(e.g., electrostatics, hydrogen bond) that contribute to the interaction (∆Gi) [23]. The weighting
coefficients are derived by fitting the predicted binding affinity data with the experimental data (crystal
structures of complexes) using multivariate regression analysis [18,23]. Finally, knowledge-based
scoring functions derive the energy function from known structures of complexes (protein–protein,
protein–ligand). Statistical analyses are then applied to derive pairwise potentials obtained directly
from experimental data [18]. The energy potentials for the pairwise atomic interactions are derived
as a function of the distance between the atoms and are then used to calculate the energies of all
conformations [24].
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To demonstrate the potential of using docking to gain a better understanding of interactions
involved in protein formulations, we applied protein–protein and protein–ligand docking on the
WW34 protein with known interactions with two amino acids—Arg and Glu.
Shukla et al. [8] combined available experimental information [7] with their molecular dynamics
simulations to evaluate the sites of interaction and excipient ratio, providing a approach that addressed
the issue from a different aspect. They also employed the preferential interaction theory to assess the
effect of excipients on protein solubility. The correlation between preferential interactions between
protein and excipients and protein solubility has been previously studied by Arakawa et al. [25].
Briefly, they showed that, if the protein is preferentially hydrated (Γ23 < 0), the interaction with
excipients is less favoured and the interaction between protein molecules is favoured to prevent
excipient interactions with the protein surface. Increased protein–protein interaction and decreased
protein–excipient interaction can often result in a decrease of protein solubility. Shukla et al. [8]
performed molecular dynamics simulations of the WW34 protein in the presence of varying molar
concentrations of Arg and Glu and equimolar ratios of the two excipients. The theoretical preferential
interaction coefficient for each system was determined from the number of excipient molecules and
water molecules as a function of their distance from the protein surface throughout the trajectory [8,26].
The authors considered the relationship between the preferential interaction coefficient and protein
solubility previously defined by Shulgin et al. [27]. The preferential interaction coefficient determined
for the protein in an equimolar mixture of L-Arg (Γ23 = 8.8) and L-Glu (Γ23 = 3.6) was higher than
for systems with only one of the excipients (Arg, Γ23 = 1.3–7 and Glu, Γ23 = 0.5–0.9). This was due
to the interactions between Arg and Glu, thus supporting that the synergistic effect of Arg and Glu
enhanced the local concentration of the amino acids on the protein surface, leading to an increased
solubility of WW34 [8]. The number of excipient molecules close to the protein surface was calculated
by determining the nearest amino acid to each one of the excipient molecules in the simulation. The
authors found that there were few sites where both Arg and Glu were present, allowing them to
establish the binding of the motifs. These interaction sites were the amino acids GLU 40, ASP41,
ARG79, and ARG71 [8]. The identified sites of interactions have been used as a benchmark to evaluate
the effectiveness of our approach.
In this study, the interaction surfaces were determined using the molecular docking, and four
different software packages were utilised for validation purposes. Two types of molecular docking
were employed: the rigid docking to determine protein–protein interactions and flexible docking
to evaluate protein–excipient interactions. For each category, two distinct software packages were
used that generate ligand poses (excipient–protein docking) or different types of scoring functions
(protein–protein docking) and evaluate the consistency of the observed poses. This provides
complementary information that should ensure the identification of possible relevant interaction
sites and aid the rational selection of excipients and the design of pharmaceutical formulations. The
details of the scoring functions for each one of the software packages included in the study can be
found in Section 3.
2.1. Hotspots for Protein Interactions with Excipients—Flexible Docking
Most protein-small molecule docking software requires some information about the binding site
for accurate results. Even though some packages allow for expansion of the area in the protein to be
considered, usually by expanding a grid or box, this leads to a loss of definition. The larger the area,
the less points within the box will be considered, thus potentially compromising the results. Software
packages where the whole protein must be screened for potential sites of interaction with excipients
would not suit the aim of this study. To develop the docking method, two different protein-small
molecules software packages were initially used: GLUE [28] and iGemDock [29].
The two software packages selected both allow whole protein docking without requiring
information on the binding site. This is crucial in this approach to rationalise screenings of excipients of
different classes that might be needed to stabilise a given protein. This means that there will likely be
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more than one hotspot (binding site) for different classes of excipients. For this study, the interactions
of arginine with the target protein were evaluated and compared with previously published data [8].
The results obtained with the GLUE software package identified two preferential sites for arginine
interaction, while iGemDock solutions were all in the same site (Figure 1). Nonetheless, the lowest
energy solution for both software packages was found to be in the same site (Figure 1). A detailed
analysis of intermolecular interactions for this hotspot revealed that the orientation of the arginine in
docking poses obtained for two docking software is different (Figure 2).
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The residues that interact with arginine are the same as previously reported [7,8]. The orientation
of the arginine molecule appears to be different. This may be due the scoring functions, which account
for the electrostatic contributions differently. Nonetheless, these preferential interaction sites on WW34
can be considered to be hotspots for arginine.
Previous studies by Shuka et al. showed that arginine molecules can form hydrogen bonds
with residues ASP41 and GLU40 [8]. The interaction map obtained with the visualiser showed the
potential for hydrogen bond formation between arginine and GLU40 in both GLUE and iGemDock.
However, only GLUE found ASP41 at a distance, which would suggest electrostatic interaction between
arginine and this residue. It is necessary to bear in mind that these are static points, and, even though
the distance between arginine and ASP41 was only identified for this kind of interaction, in a real
world situation, structures are dynamic and distances can change, leading to closer contacts. Further
molecular dynamics studies with solutions from GLUE were performed to investigate the validity of
the results obtained.
2.2. Hotspots for Protein–Protein Interactions—Rigid Docking
Two molecules of WW34 were docked against each other to identify the potential regions and
residues that could be involved in interactions between two protein molecules and could be responsible
for protein aggregation. This would allow us to evaluate if a protein–protein interface is the same as
the arginine interaction site on the protein surface identified with protein–ligand docking (Section 2.1).
Therefore, this would provide a good case study to demonstrate how the presence of this excipient is
effective in preventing such protein–protein interactions and stabilising WW34.
A number of different computational approaches have been developed to identify protein regions
responsible for aggregation. However, most of these methods utilise available experimental data and
bioinformatics tools to identify sequences of aggregation-prone regions (APR) and do not take protein
tertiary structure into account [30]. Molecular dynamics and Monte Carlo simulations have also been
used for aggregation propensity studies [30,31]. However, these are time-consuming approaches that
cannot be easily translated in the early stage formulation development environment and hence would
not be efficient for excipient selection.
We chose to utilise rigid protein–protein docking software, as it is fast and based on Fourier
transform algorithms, minimising the computational time required for the identification of surfaces that
could be responsible for aggregation. For validation purposes, two independent rigid docking software
packages were used: Hex and GRAMMX. The main difference between these is how the surfaces of
the receptor and ligand are defined and the approximations used for electrostatic contribution.
These two software packages use different scoring functions to rank the results found; therefore,
it would be expected that the orientation of the molecules given by HEX and GRAMMX would
be different, which can be observed in the lowest energy solutions for the two different packages
(Figure 3). However, despite these differences in the orientation of the two WW34 subunits under
study, the key areas for the interactions that may be responsible for aggregations are similar (Figure 3).
A closer look into residues less then 4 Å apart for the lowest energy solutions found by HEX and
GRAMMX showed that ASP41 and PRO42 were involved in interactions between subunits. The same
ASP41 has been found to be involved in interactions with arginine (Arg) and glutamic acid (Glu) in
the published molecular dynamics study by Shukla et al. [8]. The authors showed that Arg and Glu
interacted with the protein surface, reducing the number of protein–protein interactions. Amongst the
identified arginine and glutamic acid binding motifs was residue ASP41, which was also identified by
our methodology, giving a good indication of the suitability of the method.
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Figure 3. Molecular docking results of two WW34 molecules (green set as ligand and grey set as target)
depicting protein–protein interactions that could be responsible for aggregation. The residues found
to be less than 4 Å from the structure set as receptor are colored in yellow. GRAMMX, lowest energy
solution (left); HEX, lowest energy solution (right).
2.3. Molecular Dynamics Simulations—Validation of Identified Hotspots
Molecular docking software packages are designed to find and rank interactions between two
molecules. This means that we will always obtain solutions. The energy values obtained are
crucial to judge the reliability of the solutions obtained. For complexes of large molecules (e.g.,
protein–protein) or for detailed analysis of defined and known binding sites, differences in energy
values can discriminate the docking interactions. However, when docking small molecules, the
differences in energy values between solutions or even in its absolute value can be low and therefore
not enough to confidently judge on an interaction. Molecular dynamics simulations can aid the
understanding of protein–excipient interactions for systems that are well defined, as demonstrated
with 50-ns simulations of bovine serum albumin in the presence of two excipients [32].
To evaluate the dynamic behaviour of the identified interactions and to verify that the excipient
will preserve interactions observed in binding poses identified by the docking protocol, further
validation of the hotspots was conducted. The molecular dynamics simulation was performed using
one of the solutions obtained from GLUE, WW24, and two arginine molecules as a starting point. The
MD simulation was carried out on a fully solvated system using explicit solvent at 300 K and 1.03 bar
under constant number of particles, pressure, and temperature (NPT) conditions. Although we did not
evaluate the binding energy during the simulations, this allowed us to observe the interaction between
arginine and the protein residues over the period of the simulation. From the trajectory analysis, it was
possible to observe that whilst both WW34 and arginine change conformation, the interaction with
the key identified residues, GLU40 and ASP41, is maintained throughout the simulation (Figure 4),
namely the distance between selected residues and arginine always being lower than the 4-Å cut off.
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Figure 4. Snapshots of the 60-ns MD simulation performed with the solutions obtained from GLUE.
Two Arg molecules were considered so that both hotspots identified by GLUE were represented.
WW34 protein is displayed as ribbons in green and the two arginine molecules are displayed as
CPK and coloured by element. The reference residues Glu40 and Asp41 are highlighted in yellow in
each snapshot.
2.4. Application to the Fab A33 and a Set of Commercial Excipients
The method was then applied in an effort to determine the hotspots for interactions between
Fab A33 [33] and several excipients. Fabs are an emerging class of antibody fragments developed for
therapeutic applications. There are already some examples in the market such as Cimzia (UCB) and
Lucentis (Genentech), amongst others, and more are being developed [34]. Fabs can be expressed in
microbial systems, making their production process more economical in comparison to monoclonal
antibodies (mAbs) [34]. Other advantages for their use include faster tissue penetration [35,36] and the
absence of the Fc portion of antibodies [34]. The use of Fabs as therapeutics is growing, making them
an interesting case study for the application of the computational method developed. Furthermore,
they are easier to model as complex glycosylation patterns, and flexible domains found in mAbs are
not present.
The excipients selected have all been approved by FDA for parental use. As a starting point, we
utilised those that are commonly used in commercial formulations. Most of these excipients have a
stabilising role in protein formulations. Representative excipients from different classes were chosen:
two amino acids, two saccharides, two sugar alcohol isomers, and two surfactants. For the docking
experiments, the following excipients were used as ligands: arginine; glycine; sucrose; trehalose;
manitol; sorbitol; polysorbate 20; polysorbate 80.
GLUE software was used to establish the preferential spots of interaction between ligands and
A33. The ligands and there interaction with A33 were firstly compared and analysed based on their
structure and/or function similarity.
2.4.1. Hotspots for Fab A33 Interactions with Two Amino Acids
Arginine is frequently used in parentally administered formulations as a viscosity reducer [13].
However, arginine is also a mild detergent that can bind to proteins and have a negative effect, namely
in protein thermo stability [13,37]. Glycine (Gly) is routinely used in lyophilised protein formulations,
as it improves porosity and coherence of the cake [38–40].
Arginine was found to interact in three different spots in the protein and five different solutions
were retrieved (Figure 5). On the other hand, glycine retrieved only three solutions but with higher
affinity (Table 1) and only two spots (Figure 5), indicating higher specificity than arginine.
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Figure 5. Molecular docking results for arginine and glycine obtained with GLUE software. A33 is
displayed in blue ribbons, arginine in green and glycine in red (left); The higher affinity molecules are
displayed as larger CPK. A33 residues involved in each identified spot (right).
Table 1. Binding affinity and hotspot for each arginine and glycine solutions.
Molecule Arg1 Arg2 Arg3 Arg4 Arg5 Gly1 Gly2 Gly3
Ebinding kcal¨mol´1 ´25.029 ´22.737 ´19.848 ´15.913 ´15.583 ´27.304 ´26.352 ´25.334
Spot 3 1 3 2 2 1 2 1
2.4.2. Hotspots for Fab A33 Interactions with Two Saccharides
Trehalose and sucrose are non-reducing disaccharides that ar commonly used for the f eeze-
drying of therapeutic prot ins for parenteral administration, namely m noclonal antib dies [41–44].
A total of 15 solutions were obtained for trehalose and 13 for sucrose. Whilst for trehalose the lowest
energy solutions all interacted on the same two spots, for sucrose four spots were found for the
five lowest energy structures, showing much lower specificity in the interaction (Figure 6; Table 2).
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Figure 6. Molecul r docking results for trehalose and sucros obtained w th GLUE software. A33 is
displayed in blue ribbons, trehalose in black, and sucrose in pink (left); The higher affinity molecules
are displayed as larger CPK. A33 residues involved in each identified spot (right).
Table 2. Binding affinity and hotspots for the five lowest energy solutions found for the trehalose and
sucrose solutions.
Molecule Tre1 Tre2 Tre3 Tre4 Tre5 Suc1 Suc2 Suc3 Suc4 Suc5
Ebinding kcal¨mol´1 ´16.638 ´13.783 ´13.023 ´12.262 ´11.762 ´20.233 ´16.780 ´16.334 ´13.868 ´13.286
Spot 2 1 2 1 1 2 1 1 3 4
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2.4.3. Hotspots for Fab A33 Interactions with Two Sugar Alcohol Isomers
Mannitol and sorbitol are monosaccharide-derived polyols that are commonly used as
pharmaceutical excipients (e.g., diluents in tablets). More relevant to this study, these are also used as
carriers to improve cake homogeneity and the appearance of lyophilised products [45–47]. Despite
being isomers, slight differences are often observed between mannitol and sorbitol. Mannitol displayed
a higher number of solutions (19) than sorbitol (18), and an overall higher affinity (Table 3). Both
molecules mostly interacted in the same two hotspots for the top five docking solutions, except from
the structures with lower binding affinity, which interacted in a different spot (Figure 7).
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2.4.4. Hotspots for Fab A33 Interactions with Two Surfactants 
Polysorbates are effective at preventing physical and chemical instability during processing and 
freeze-thaw cycles, even at very low concentrations, and they have relatively low toxicity [48]. 
There were no differences between polysorbate 20 and 80 in term of number of solutions, 
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Figure 7. Molecular docking results for mannitol and sorbitol obtained with GLUE software. A33 is
displayed in blue ribbons, mannitol in green, and sorbitol in light blue (left); The higher affinity
molecules are displayed as CPK and lowest as tubes. A33 residues involved in each identified
spot (right).
Table 3. Binding affinity and hotspots for the five lowest energy solutions found for mannitol and
sorbitol solutions.
Molecule Man1 Man2 Man3 Man4 Man5 Sor1 Sor2 Sor3 Sor4 Sor5
Ebinding kcal¨mol´1 ´11.901 ´10.67 ´8.537 ´8.415 ´7.852 ´9.879 ´9.372 ´8.904 ´8.524 ´8.329
Spot 1 1 2 3 1 2 1 1 1 4
2.4.4. Hotspots for Fab A33 Interactions with Two Surfactants
Polysorbates are effective at preventing physical and chemical instability during processing and
freeze-thaw cycles, ev n at very low concentrations, and they have relatively low toxicity [48].
There were no differences between polysorbate 20 and 80 in term of number of solutions,
interaction spots or binding affinity (Figure 8; Table 4).
Table 4. Binding affinity and hotspot for the lowest energy solutions found for polysorbate 20 and
80 solutions.
Molecule
P20 P20 P20 P20 P80 P80 P80
1 2 3 4 1 2 3
Ebinding kcal¨mol´1 ´21.3 ´18.3 ´15.6 ´14.4 ´20.6 ´20.1 ´18.9
Spot 2 3 1 1 2 3 1
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Figure 8. Molecular Docking results for polysorbate 20 and 80 obtained with GLUE software. A33 is
displayed in blue ribbons, polysorbates are represented in green and purple (left); The higher affinity
molecules are displayed as CPK and lowest as tube or ball and stick. A33 residues involved in each
identified spot (right).
2.5. Hotspots for Fab A33 Interactions with Excipients
In addition to the above analysis where the number of docking solutions and spots of interactions
were analysed for each excipient in the study, the three highest affinity solutions for each ligand were
further inspected. The interaction framework of these molecules and the interaction spot on A33 was
determined and plotted. This allowed for the determination of the A33 residues involved to evaluate
the nature of the interactions in an effort to understand the differences observed in the binding energy
values for each excipient. Figure 9 shows an example of this interaction framework. In this example,
it is possible to see how the relatively high-energy values observed for sorbitol correspond to a low
binding affinity and reflect the weak nature of its interactions with the protein.
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With all the information collected, it was possible to identify and define three hotspots for the
interaction of A33 with the excipients (Figure 10; Table 5): one hotspot where sucrose and trehalose
interacted most favourably, a second hotspot where both saccharides and amino acids interact, and
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finally the third hotspot where only surfactants docked (Figure 10). Hotspots 2 and 3 are located
mainly in the light chain of A33 (Table 5).Int. J. Mol. Sci. 2016, 17, 853 12 of 20 
 
 
Figure 10. Frontal (left) and side (center) views of the three hotspots for A33–excipient interaction 
identified. A33 residues involved in each hotspot highlighted in yellow (right). A33 is represented as 
ribbons with the heavy chain in dark blue and the light chain in green. The representative structures 
of the excipients are displayed in CPK, trehalose—black; sucrose—pink; arginine—light green; 
glycine—orange; manitol—salmon; sorbitol—dark green; polysorbate 20—magenta and polysorbate 
80—purple. 
Table 5. Description of the three hotspots identified for A33-based on the interaction with a set of 
commercial excipients. 
Excipient Ebindingkcal·mol−1 Hotspot in Target 
Trehalose_1 −13.8 Hotspot 1  
Heavy Chain: Lys43-Trp47; Arg67; Glu89  
Light Chain: Ile1-Trp5; Thr97-Gln100 
Trehalose_2 −12.3 
Sucrose_1 −16.9 
Sucrose_2 −13.9 
Arginine_1 −22.7 
Hotspot 2  
Heavy Chain: Ser131-Ser136  
Light Chain: Ala112-Ile117; Leu201-Asn210; Glu213-Cys214 
Glycine_1 −27.3 
Glycine_2 −25.3 
Mannitol_1 −11.9 
Mannitol_2 −10.7 
Mannitol_3 −7.8 
Sorbitol_1 −9.4 
Sorbitol_2 −8.9 
Sorbitol_3 −8.5 
Tween20_1 −14.4 Hotspot 3  
Heavy Chain: Val2-Leu4; Ala105-Trp107; Gln109  
Light Chain: Lys39; Lys42-Thr46; His55-Val58; Pro80-Phe83; Gln166-Ser168 
Tween20_2 −15.6 
Tween80_1 −18.9 
2.6. Protein–Protein Interaction Surfaces between Two Fab A33 Molecules 
Hex was used to perform protein–protein docking with Fab A33. This allowed further 
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Figure 10. Frontal (left) and side (center) views of the three hotspots for A33–excipient interaction
identified. A33 residues involved in each hotspot highlighted in yellow (right). A33 is represented as
ribbons ith the heavy chain in dark blue and the light chain in green. The representative structures
of the excipients are displayed in CPK, trehalose black; sucrose pink; arginine light green;
glycine orange; anitol sal on; sorbitol dark green; polysorbate 20 agenta and polysorbate
80 purple.
Table 5. Description of the three hotspots identified for A33-based on the interaction with a set of
co ercial excipients.
Exci ie t Ebinding kcal¨mol´1 Hotspot in Target
Trehalose_1 ´13.8 Hotspot 1
Heavy Chain: Lys43-Trp47; Arg67; Glu89
Light Chain: Ile1-Trp5; Thr97-Gln100
Trehalose_2 ´12.3
Sucrose_1 ´16.9
Sucrose_2 ´13.9
Arginine_1 ´22.7
Hotspot 2
Heavy Chain: Ser131-Ser136
Light Chain: Ala112-Ile117; Leu201-Asn210; Glu213-Cys214
Glycine_1 ´27.3
Glyci 2 ´25.3
Mannitol_1 ´11.9
Mannitol_2 ´10.7
Mannitol_3 ´7.8
Sorbitol_1 ´9.4
Sorbitol_2 ´8.9
Sorbit l 3 ´8.5
Tween20_1 ´14.4 Hotspot 3
Heavy Chain: Val2-Leu4; Ala105-Trp107; Gln109
Light Chain: Lys39; Lys42-Thr46; His55-Val58; Pro80-Phe83; Gln166-Ser168
Tween20_2 ´15.6
Tween80_1 ´18.9
2.6. Protein–Protein Interaction Surfaces between Two Fab A33 Molecules
Hex was used to perform protein–protein docking with Fab A33. This allowed further validation
of the hotspots by evaluating if the residues that were involved in the interaction between two Fab
A33 molecule were the same as the on s interacting with the excipients. Figure 11 shows one of the
obtained solu ions from the molecular docking xperiment. Fo this analys s, three lowest nergy
solutions were c nsid red (Table 6).
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The hotspots found for the protein–excipient interactions are located in regions prone to
interactions between two A33 molecules. These interactions potentially lead to protein aggregation
that can be prevented if the excipients are added to the protein.
2.7. Experimental Confirmation of the Presence of Interaction between A33 and the Commercial Excipients
Thermal analysis was conducted with the Fab A33 in the presence and absence of excipients to
quickly and qualitatively assess whether there was an effect of the presence of the excipients on the
Fab melting temperature (Tm) to further support the docking results. Protein Tm can be affected by a
variety of factors and can be used to monitor unfolding and aggregation phenomena [49]. Excipients
are known to impact the thermodynamic behaviour of proteins and affect Tm values [13]. The melting
temperature of A33 and combinations of A33 and the excipients used in the docking calculations
was determined using the OPTIM 1000 (Avacta). These experiments aimed to demonstrate only the
presence of an effect driven by protein–excipient interactions, since no screening for the optimisation
of the stoichiometry between protein and excipient was conducted.
Table 7 shows the Tm values determined for each of the conditions tested. Overall, all excipients,
except Arg, appeared to positively affect the Tm of A33. The adverse effect of Arg in A33 Tm value was
expected since, as mentioned above, arginine can act as a mild detergent [13,37].
Without screening the concentration of the excipients and the proportion with the protein, it is not
possible to make quantitative considerations on this effect or which excipient can provide better results.
However, these results further confirm an interaction between excipients and protein and their potential
to stabilise protein. Finally, the docking results for all excipients except arginine (negative control,
different mechanism) were correlated with the melting temperatures (Figure 12). The correlation
shows that the computational method described was able to describe 74% of the experimental space,
providing a basis for the rational selection of excipients in formulation design experiments.
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Table 7. Tm values determined for Fab A33 with and without excipients. All experiments were
performed in 10 mM phosphate buffer, pH 7; the average standard deviation was 0.28. Average binding
affinity values from docking experiments above.
Sample Concentration Tm (˝C) Average Ebinding kcal¨mol´1
A33 1 mg/mL 79.37 -
A33 + trehalose 5% w/v 80.4 ´13.05
A33 + sucrose 5% w/v 80.16 ´15.4
A33 + mannitol 4% w/v 80.06 ´10.13
A33 + sorbitol 4% w/v 80.3 ´8.93
A33 + Tween 20 0.4% w/v 80.5 ´15.00
A33 + Tween 80 0.4% w/v 80.1 ´18.9
A33 + Gly 2% w/v 81.6 ´26.3
A33 + Arg 2% w/v 71.6 ´22.7
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3. Materials and Methods 
3.1. Molecular Structures Setup 
The structures of all excipients were drawn in Maestro 10.3 (Schrodinger, LLC, New York, NY, 
USA) and a short minimisation protocol was performed using Macromodel 10.0 (Schrodinger, LLC, 
New York, NY, USA). The Drosophila Su(dx) (WW34) structure was taken from PDB 1TK7 [50].  
The 3D structure of Fab A33 is a homology model previously built at UCL. The protein structures 
were verified and optimised with the Prep Wiz tool from Maestro 10.3 (Schrodinger, LLC,  
New York, NY, USA). 
3.2. Protein-Protein Molecular Docking 
The docking of two protein molecules to determine interaction surfaces that could be 
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Figure 12. Correlation between molecular docking results, expressed as a binding affinity and
experimental results, Tm.
3. Materials and Methods
3.1. Molecular Structures Setup
The structures of all excipients were drawn in Maestro 10.3 (Schrodinger, LLC, New York, NY,
USA) and a short minimisation protocol was performed using Macromodel 10.0 (Schrodinger, LLC,
New York, NY, USA). The Drosophila Su(dx) (WW34) structure was taken from PDB 1TK7 [50]. The 3D
structure of Fab A33 is a homology model previously built at UCL. The protein structures were verified
and optimised with the Prep Wiz tool from Maestro 10.3 (Schrodinger, LLC, New York, NY, USA).
3.2. Protein-Protein Molecular Docking
The docking of two protein molecules to determine interaction surfaces that could be responsible
for the aggregation was performed using Hex; with its shape and electrostatic protocol, the scan steps
were set to 0.75 with two substeps. The docking correlation order was set to 25 for steric scan and
25 for the fine search. The grid size was set to 1, and 100 solutions were recorded. Of these, the
first structures of the first 10 clusters were saved as PDB files. The same experiment was performed
using the web server GRAMM-X (Lawrence, MA, USA). The results were processed using Discovery
Studio 4.0 (Biovia, San Diego, CA, USA). A 4-Å cutoff was allowed to identify residues involved in
protein–protein interactions.
The Hex software package was used for the protein and nucleic acids interaction studies, though it
also allows small protein–ligand interactions with a rigid ligand. Hex is a fast Fourier transform (FFT)
docking correlation-based program; however, unlike previously developed programs, it uses soft polar
Fourier correlations, minimising the computational time required to explore the Cartesian space [51,52].
The molecular surface of the proteins are represented by an internal and an external “skin”, each
one of them being represented by a Fourier series comprising radial and spherical harmonic basis
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functions [51]. Electrostatic contribution is optional, but, when present, it is only taken into account
in the final search, having a small weight in the final scoring function. The resulting structures are
ordered from lowest to highest energy, and the structures are then clustered with a 3-Å threshold for
the main chain Cα–Cα RMSD values [53].
GRAMM-X is also a fast Fourier transform (FFT)-based software that applies smoothed Lennard
Jones potentials, refinement, and knowledge-based scoring. With this package, proteins are represented
by a fine-grid softened by Lennard-Jones potential function calculated for a probe atom:
Vij prq “ 1
ασ6ij ` r6
˜
4εijσ12ij
ασ6ij ` r6
´ 4εijσ6ij
¸
(1)
The optimal values of the parameters for a typical protein in unbound conformation are α = 0.4,
σ = 0.33 nm, and ε = 0.5, these are applied to all non-hydrogen atoms. The top 4000 grid-based
predictions are subjected to a conjugate gradient minimisation in continuous 6D rigid body space
with the same soft potential [54]. The minimisation accumulates many points—some in local minima.
One representative prediction for each minimum is stored, and the number of initial predictions falling
into this minimum is marked as the volume of the minimum. The average radius of such minima on
the smoothed landscape is 5 Å. For each minimised prediction, the following terms are calculated:
the soft Lennard-Jones potential, the evolutionary conservation of predicted interface, the statistical
residue–residue preference, the volume of the minimum, the empirical binding free energy, and the
atomic contact energy [54]. To eliminate predictions that are likely to be located far from the correct
binding site, a support vector machine filter is applied. The remaining predictions are then re-scored
by a weighted sum of the potential terms [54].
3.3. Protein–Excipient Molecular Docking
Molecular docking with GLUE was performed using GRID protocol. The three components of
the GRID (Molecular Discovery Ltd., London, UK) protocol were used in these studies. GREATER
(Molecular Discovery Ltd., London, UK) was used to generate the KOUT files for all molecules
involved. GLUE (Molecular Discovery Ltd., London, UK) requires either KOUT or MOL2 files for
the docking process. For this study, the PDB files were converted to KOUT files. For the docking
process, with GLUE, all available probes were selected, and a maximum number of 100 binding sites
were used with an energy cut off of ´100 Kcal/mol. The maximum iteration value was set to 120.
For ligand flexibility, 5 rotatable bonds were allowed, and electrostatics was included. Arginine and
the selected commercially used excipients were used as ligands. The Drosophila Su(dx) structure
(1TK7) and homology model of A33 were set targets. The same structure was docked with iGemDock
(BioXGem, Hsinchu, Taiwan). The docking accuracy was set to the “Accurate Docking” setting by
choosing a population size of 800 with 10 generations to produce 10 solutions. The docked ligand
conformations were then re-ranked for the post-docking analysis. A 4-Å cutoff was allowed to identify
residues involved in protein–protein interactions. A cutoff of 3.5 Å was used to build the interaction
maps involved in the interaction with excipients.
GRID is a calculation-based procedure that allows for the determination of energetically
favourable binding sites on a molecule with a known structure. GRID has been used to study nucleic
acids and individual molecules such as drugs or macromolecules (such as proteins) [28]. GRID also
enables the study of several different molecules consecutively. GRID results can be visualised with
GView, which allows molecular interaction fields, GRID energy contributions due to atoms of the target,
and molecular structures with distances, torsion, and dihedral angles to be viewed. The graphical user
interface (GUI) provides access to the GRID software package and is strongly integrated with GView,
helping users to visualise the structure of the Target and the results of the GRID computation at the
same time. GLUE is a GRID-docking programme capable of finding possible interaction sites between
a molecule set as “target” and a small molecule called a ligand. It requires the input of the 3D-structures
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of both target and ligand, and it allows visualisation of the docking process. Its scoring function takes
into account steric repulsion energy, electrostatics contribution, a dry parameter, which accounts for
hydrophobic energy, and an additional hydrogen bonding charge-reinforcing parameter [28].
The second docking package that was evaluated is iGemDock [29]. This flexible ligand-docking
software uses an empirical scoring function and a genetic evolutionary method for molecular
docking [29,55]. The energy function can be described by
Etot “ Ebind ` Epharma ` Eligpre (2)
where Ebind accounts for inter- and intra-molecular energies and an additional Epenal, and, in case the
ligand is outside the search box, its fixed value is 10,000. The Epharma term is the sum of all hot-spot
atoms of the interaction between ligand and protein:
Epharma “
ligÿ
i´1
hsÿ
j´1
f
`
wj, Bij
˘
F
´
r
Bij
ij
¯
(3)
where wj is the pharmacophore weight of the hot-spot atom j, r
Bij
ij is the distance between the atoms i
and j with the interaction type Bij forming by the pair-wise heavy atoms between ligands and proteins;
Bij is either a hydrogen bond or a steric state; lig is the number of heavy atoms in the ligand; and hs
is the number of hot-spot atoms in the receptor. The value of f (wj, Bij) is wj or 0. f (wj, Bij) is wj if the
interaction type (Bij) equals the type of hotspots found on the target receptor. The ligand preferences
include electrostatic (i.e., the number of electrostatic atoms) and hydrophilic characteristic (i.e., the
atom numbers of hydrogen donor and acceptor). The Eligpre is a penalty value for a ligand, which is
unable to satisfy the ligand preferences and is defined as
Eligpre = WPelec + WPhb (4)
where WPelec and WPhb are the penalties for the electrostatic and hydrophilic preferences,
respectively [56]. iGemDock required the input of the coordinates of target protein atoms from the PDB
format file and sequentially read the atom coordinates of a ligand from the prepared ligand database.
The ligand database and the target protein were prepared and sequentially performed the flexible
docking for each ligand by using the genetic algorithm implemented in GemDock [30]. Its energy
function consists of electrostatic, steric, and hydrogen-bonding potentials. The latter two terms use a
linear model that is simple and recognises potential complexes rapidly [29].
3.4. Molecular Dynamic Simulations
Molecular dynamics simulations were performed with the top scores for 1TK7 and arginine from
both GLUE and iGemDock. The simulations were performed with Desmond [57] within the Maestro
environment. The molecular dynamics simulation, minimisation, and relaxation steps were performed
for 60 ns at 300 K and 1.03 bar, and in a buffer zone of 10 Å. Snapshot structures were recorded every
5 ps. The simulation event analysis tool for trajectory analysis within Maestro (GUI) was used to
perform RMSD and RMSF calculations and measurements such as hydrogen bonds, distances, and
gyration radius along the trajectory. Snapshots from the trajectory were exported every 15 ns for
further analysis with Discovery Studio (Accelerys). A 4-Å cutoff was allowed to identify residues
involved in protein–excipient interactions.
Molecular dynamics methods calculate the forces between the atoms at each time-step, and from
that these methods are designed to calculate the new positions and velocities of all of the atoms by
applying classical laws of physics [58]. Desmond is a MD code, which allows parallel scalability
for clusters, improving simulation throughput, and reducing computational time. It comprises a
series of methods and algorithms that accelerate MD simulations, including a parallel decomposition
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method and message-passing techniques that reduce communication requirements, as well as
novel communication primitives that further reduce communication time. Its numerical techniques
maintain high accuracy while using single precision computation in order to exploit processor-level
vector instructions.
3.5. Stepped Thermal Experiments to Determine Tm Values
Chemicals including trehalose, sucrose, glycine, arginine, mannitol, sorbitol, Tween 20, Tween 80,
and sodium phosphate were purchased from Sigma-Aldrich (Poole, Dorset, UK). Excipients, sodium
phosphate and purified Fab were prepared in stock solutions and mixed together to reach a final
concentration of 1 mg/mL of Fab in 10 mM phosphate buffer at pH 7. The final concentration of
excipient was variable: 5% (w/v) for trehalose and sucrose, 2% (w/v) for glycine and arginine, 4% (w/v)
for mannitol and sorbitol, and 0.4% (w/v) for Tween 20 and Tween 80. Avacta OPTIM 1000 (Thorp Arch
Estate, Wetherby, UK) was used to perform the stepped thermal unfolding study. The samples were
ramped from 20 to 90 ˝C at 1 ˝C per step, with a temperature tolerance of 0.2 ˝C. Tm was determined
as described by Chakroun et al. [59].
4. Conclusions
A combination of molecular docking methods has been successfully utilised to predict hotspots in
protein excipient interfaces in a Drosophila Su(dx) protein (WW34). The positive effect of the presence
of excipients in the proximity of these hotspots was confirmed by molecular dynamics simulations,
thereby validating this approach for predicting interaction interfaces. Furthermore, possible favourable
interactions between Fab A33 and several excipients predicted by docking were confirmed qualitatively
by Tm values from a stepped thermal study. The computational methods that provide information
about the intermolecular interactions between excipients and proteins could play an important role
in the design of therapeutic protein formulations during development. Molecular docking provides
the means for the rapid identification of molecules that can form favourable interactions with protein
surfaces, hence enabling a rational approach in the design of experimental formulation development
and a more effective use of the small amounts of protein therapeutics that are usually available in early
stage development.
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